DLA Piper Life Sciences Sector

We are delighted to announce that our team in Germany has been shortlisted for Team of the Year: Healthcare, for the Legal 500 Germany 2025 Awards, which recognise the lawyers and law firms setting the pace across the country. Congratulations to the team including Dr. med. Kokularajah Paheenthararajah, Dr Benjamin Parameswaran, Mathias Schulze Steinen, Dr. Nils Krause, LL.M. (Durham), Lars Jessen, Dr. Moritz von Hesberg, MBA (UCT), Prof. Dr. Stefan Engels, Dr. Philipp Cepl, Dr. Thilo von Bodungen, Dr. Christian Schoop, Dr. Burkhard Führmeyer, Jan Pohle, Prof. Dr. Ludger Giesberts, LL.M. (LSE), Guido Kleve, Dr. Thilo Streit LL.M. (UT Austin), Sebastian M., Nicole Saurin, Cristina Helena Villafrade, Dr. Isaschar Nicolaysen, LL.M., Till Burmeister, Daniel Osmanovic, Rune Jelte Weltz LL.M. (University of Cape Town), Andreas Rüdiger, Hauke Tammert, Dario Westarp, Dr. Anna Deborah Fink, Pia Riemenschneider, LL.M., Carl Prior, Mikael Kurki, Sarah-Maria Hudetz, Lisa Fleckenstein and Dr. Lukas Gerhardinger for their valuable contributions throughout the year. We look forward to celebrating with the other finalists at the awards ceremony in Frankfurt on 21 February, 2025.

In Part 3 of our publication series on the European Health Data Space, Andreas Rüdiger and James Clark provide an overview of the framework for accessing health data for secondary use under the EHDS. The article details the application process, the role of Health Data Access Bodies, and the safeguards in place to protect intellectual property and trade secrets. Click below to read more. #HealthTech #EHDS #MedicalResearch #DataSecurity #LifeSciences

We recently held our annual Global Life Sciences Summit 2024 in London, which was attended by over 200 industry stakeholders from 25 jurisdictions. We are delighted to share some of the highlights from our plenary sessions, which focused on the key trends impacting the sector: - Marco de Morpurgo set the scene for the day with our theme - futureproofing for the next decade; - Former Head of EMA Legal Department Stefano Marino gave his insights on recent changes to EU pharmaceutical legislation; - Former US Senator Richard Burr and Former European Commissioner Phil Hogan discussed the political challenges facing the industry, including the recent elections across Europe and the US; - Lyndsey Olivia Hudson discussed the future of the life sciences industry from 2024 – 2034, including the impact data and intelligent tech will have on the sector; - Jeff Baglio spoke with Bill Burkoth and Karl Keegan about what is driving the market, highlighting that investment in the sector should improve in 2025; - Tom Heylen interviewed Shaun Walden about ESG & sustainability issues with Shaun emphasising the importance of governance in managing ESG risks; and - Gareth Stokes and Danny Tobey, M.D., J.D. led a panel with Debbi Bolton , Benjamin Meany and Imogen Palmer to discuss AI's role in unlocking the future of the life sciences industry. A big thank you to our speakers and clients for their valuable contributions throughout the day. For further information about any of these sessions, please contact [email protected]

In the latest article of our Genomics series, Adam Vause, Celia Johnson-Morgan and Katie Edwards explore how the UAE is pioneering the integration of genomics into its healthcare system to deliver world-class medical services. This article looks at the current landscape, future trends, and considers the potential challenges for stakeholders seeking to leverage the UAE’s commitment to advancing genomics in healthcare. Click here to read more: https://lnkd.in/e4Zp8VVP #Genomics #Healthcare #Innovation #LifeSciences

Curious about the current state of CRISPR/Cas9 patent disputes in Australia??In the latest article of our Life Sciences Genomics series, Nicholas Tyacke and Alex May highlight the complexities and opportunities in this evolving field, as well as the key patent filings in 2013 that sought to capitalise on this development. Read the full article here: https://lnkd.in/euW3Fdsk #CRISPR #Genomics #PatentLaw #Biotech #LifeSciences

We brought together more than 200 industry stakeholders from across 25 jurisdictions to discuss emerging trends and challenges facing the life sciences sector at our annual Global Life Sciences Summit in London. As part of the theme 'futureproofing for the next decade', the Summit featured discussions on a broad range of topics including the latest scientific and technological innovations shaping the industry, capital market dynamics, geopolitical opportunities and challenges. Speakers unpacked reforms of the EU pharma law and the continued importance of ESG despite artificial intelligence taking the sector by storm. Several breakout sessions covered prominent life sciences-specific legal issues facing in-house counsel today, offering vital insights and generating positive conversations. Thank you to all our speakers, clients, and colleagues for their valuable contributions. We look forward to seeing you at next year's Summit.

Andrzej Balicki, Ph.D., Jolanta D?browicz, Przemys?aw Matuszewski and Urszula Gr?bowska from our Life Sciences team, share their latest monthly briefing, covering updates and insights on medicinal products, medical devices, healthcare, food, and veterinary medicine in the Polish market.

Medicines Australia has released the latest edition of its Code of Conduct, setting new standards for ethical practices and transparency in the industry. This update emphasises the importance of integrity in interactions with healthcare professionals and patient organisations. ? Nicholas Tyacke, Greg Bodulovic, Alexandra de Zwart and Hazel P. outline the key considerations in our latest article. Click the link below to read more. ? #Pharmaceuticals #LifeSciences #MedicinesAustralia #Healthcare

At next Wednesday's Global Life Sciences Summit 2024 in London, delegates will have the opportunity to choose between nine breakout sessions, led by industry leaders and DLA Piper life sciences specialists. One of our breakout sessions will focus on life sciences M&A trends in the current environment. Victoria Rhodes and Andrew Gilbert will be joined by Gil Bar-Nahum, PhD (Jefferies International Limited), Michael Stewart (Sanofi) and Howard Taylor (Rosemont Pharmaceuticals) to discuss key issues including: - Current trends and state of the market; - How M&A has fared through a year of political change globally; and - Predictions?for the next few years and beyond. If you would like to attend the session, please register your interest?today https://lnkd.in/dVJYA-Ad

In the latest instalment of DLA Piper’s Genomics Series, the focus shifts to the regulatory landscape surrounding gene-edited plants and gene drives. As advancements in genomics continue to accelerate, Mikael Kurki, Pia Riemenschneider, LL.M. and Lisa W. delve into the complexities and evolving frameworks that govern these innovations. From the potential of gene-edited crops to revolutionise agriculture to the ethical and safety considerations of gene drives, this piece provides a comprehensive overview of the current regulatory challenges and future directions in the field. Click on the link to read the article: https://lnkd.in/efgSPeBN #Genomics #GeneEditing #Biotechnology #Regulation #GeneDrives #LifeSciences